--- a
+++ b/clusters/3009knumclusters/clust_96.txt
@@ -0,0 +1,592 @@
+Serum albumin >= 2 g/dL
+Albumin >= 2.5 g/dL within 30 days of day 1 of study
+Serum albumin >= 2 g/dL
+Serum albumin >= 2 g/dL
+Serum albumin >= 2 g/dL
+Serum albumin >= 2 g/dL
+Serum albumin >= 2.5 g/dL
+Serum albumin >= 2.7 g/dL
+Serum albumin >= 2.5 g/dL
+Serum albumin >= 2.8 g/dL
+Within 2 weeks prior to registration: Serum albumin >= 2.8 g/dL
+Albumin > 3 mg/dl
+Serum albumin >= 2.8 g/dL
+Patients with solid tumors: serum albumin >= 2 g/dL
+Serum albumin >= 2 g/dL
+Serum albumin >= 2 g/dL
+Serum albumin >= 2 g/dL
+Serum albumin >= 2 g/dL
+Serum albumin >= 2 g/dL
+Albumin >= 2.8 g/dL
+Serum albumin < 3 g/dL
+Albumin >= 2 g/dl
+Albumin >= 3.0 g/dL (within 14 days of treatment initiation)
+Within 14 days of treatment initiation: Albumin >= 2.5 g/dL
+Serum albumin >= 2.8 g/dl
+Albumin >= 2.5 mg/dL (up to 14 days before treatment initiation)
+Serum albumin > 2.7 g/dL
+Calcium >= LLN (corrected for serum albumin, if albumin abnormal)
+Serum albumin >= 2 g/dL
+Albumin >= 2.5 mg/dL
+Within 10 days of treatment initiation: Albumin >= 2.5 mg/dL
+Serum albumin ? 2.8 g/dL
+Albumin > 2.5 mg/dL
+Albumin >= 2.5 mg/dL, performed within 10 days of treatment initiation
+Albumin >= 2.5 mg/dL
+Albumin >= 2.5 g/dL, performed within 14 days of treatment initiation
+Albumin >= 2.0 g/dL
+Albumin ? 2.0 g/dL
+COHORT 1: Albumin > 2.5 mg/dL within 14 days of treatment initiation
+COHORT 2: Albumin > 2.5 mg/dL within 14 days of treatment initiation
+Serum albumin >= 30 g/L
+Albumin ?3 g/dL
+Albumin >= 2.5 mg/dL
+Albumin >= 3.0 g/dL within 14 days of starting cycle 1 day 1 treatment
+Albumin >= 2.5 g/dL
+Serum albumin ?3.0 gm/dL;
+Serum albumin >= 2.8 g/dl, within 14 days before the first dose of cabozantinib
+Serum albumin >= 2.5
+Serum albumin >= 2 g/dL
+Serum albumin >= 2.8 g/dl within 7 days before the first dose of cabozantinib
+Albumin > 3.0 g/dL.
+Albumin > 2.5 mg/dL
+Albumin > 2.5 mg/dL
+Albumin > 3 g/dL
+Within 10 (except as noted) days of planned treatment initiation: Albumin >= 2.5 mg/dL (may be within 28 days)
+Dose Escalation: Must have a serum albumin during Screening of >= 3.2 g/ dL.
+Albumin >= 2.5 mg/dl
+Albumin >= 2.5 mg/dL.
+Serum albumin ?3.5 g/dL (?35 grams per liter (g/L));
+Serum albumin < 3.0 g/dL unless prothrombin time is within the normal range
+Albumin >= 2.8 g/dL
+Obtained =< 2 weeks prior to registration: Albumin >= 3.0 g/dL
+Serum albumin >= 3.0 g/dL performed within 30 days prior to the date of registration
+Albumin >= 2.5 mg/dL, performed within 10 days of treatment initiation
+Within 14 days of treatment registration: Albumin >= 2.5 mg/dL
+Serum albumin < 2.9 g/dL.
+Serum albumin >= 2.5 g/dL
+Serum albumin >= 2 g/dL
+Serum albumin >= 2 g/dL
+Serum albumin >= 2 g/dL
+Serum albumin >= 2.8 g/dL
+Serum albumin ? 3.0 g/dL
+Documented within 14 days of registration: Albumin >= 3 g/dL
+Serum albumin >= 2 g/dL
+Subjects with serum calcium (corrected for albumin) ? 12 mg/dL
+Serum albumin ? 3 g/dL
+Albumin >= 2.5 mg/dL, performed within 14 days of treatment initiation
+Albumin >= 2.5 mg/dL within 14 days of treatment initiation
+Albumin >= 2 g/dL
+Albumin >= 2.4 g/dL
+Albumin >= 2.5 mg/dL (performed within 28 days of treatment initiation)
+Serum albumin ?2.5 g/dL.
+Albumin >= 2 mg/dL
+Albumin >= 2.5 mg/dL, performed within 28 days of study registration
+Albumin ? 3.0 g/dL.
+Albumin >= 2.5 mg/dL
+Albumin > 25 g/L
+Albumin >= 2 g/dl
+Serum albumin >= 2.5 g/dL
+Serum albumin >= 3 g/dL
+Serum albumin >= 2 g/dL
+Serum Albumin < 2.5 g/dL
+Within 14 days of randomization: Albumin > 30 g/L
+Serum albumin >= 2 g/dL.
+Serum albumin >= 2.8 g/dL.
+Albumin >= 2.5 g/dl
+Albumin > 2.8 g/dL.
+Albumin ? 3.0 g/dl
+Serum albumin >= LLN or 3 g/dl
+Albumin >= 2.5 mg/dL, performed within 28 days of treatment initiation
+Albumin >= 2.5 mg/dL, should be performed within 10 days of treatment initiation
+Albumin at least 2.8 g/dL
+Must have serum albumin > 2.5 mg/dL without intravenous supplementation
+Within 28 days prior to treatment start: Albumin >= 3.0 g/dL
+Albumin >= 3.0.
+Serum albumin ? 2.0 g/dL
+Albumin >= 3.2 mg/dL
+Albumin >= 2.5 mg/dL, performed within 10 days of treatment
+Albumin > 2.5 mg/dL within 21 days of treatment initiation
+Decreased serum albumin < 30 g/L (< 3 g/dL)
+Serum albumin concentration ?30 g/L
+Albumin >= 2.5 mg/dL within 21 days of treatment initiation
+Serum albumin >= 3.0 g/dL
+Should be performed within 30 days of treatment initiation: albumin ? 2.5 mg/dL
+Within 28 days of cycle 1 day 1: Albumin >= 2.5 mg/dL
+Albumin >= 2.5 mg/dL (performed within 10 days of treatment initiation)
+Within 5 days prior to the start of study treatment: Albumin: >= 2.5 mg/dL.
+Albumin > 2.7 g/dL
+Serum albumin >= 2 g/dl
+Serum albumin ?2.5 g/dL
+Serum albumin >= 2 g/dL
+Serum albumin >= 2 gm/dL
+Albumin >= 3 g/dL, within 14 days of registration and within 7 days of the start of treatment
+Albumin >= 2.8 g/dL
+Albumin >= 3.0 g/dL
+Obtained within 28 days prior to the first dose of cabozantinib: serum albumin >= 2.8 g/dl.
+Serum albumin >= 3.0 g/dL
+Albumin >= 2.5 mg/dL
+Albumin >= 2.5 g/dL
+Albumin >= 2.5 mg/dL, performed within 14 days of treatment initiation
+Albumin >= 2.5 mg/dL, performed within 28 days of treatment initiation
+Within 3 days before the first dose of study drug: albumin > 2.7 g/dL
+Serum albumin >= 2 g/dL
+Albumin >= 2.5 mg/dL
+Albumin > 2.5 mg/dL.
+To be performed within 14 days of treatment initiation: albumin ? 2.5 mg/dL
+Albumin ? 2.5 mg/dL within 14 days of treatment initiation
+Albumin > 2.5 mg/dL
+Serum albumin >= 2.8 g/dL
+Within 10 days of treatment initiation: Albumin >= 2.5 mg/dL.
+Within 10 days of treatment initiation: Albumin >= 2.5 mg/dL
+Within 14 days of treatment initiation: Albumin >= 2.5 mg/dL
+Albumin >= 3.5 g/dL, obtained within 7 days prior to first study treatment
+Performed within 10 days of treatment initiation: Albumin >= 2.0 mg/dL
+Serum albumin >= 3 g/dl.
+Albumin >= 2.5 mg/dL.
+Obtained =< 14 days prior to registration: Albumin >= 2.5 mg/dL
+Within 10 days prior to on-study date: Albumin ? 2.5 mg/dL
+Albumin > 3.0 mg/dL
+Serum albumin >= 3.0 g/dL
+Serum albumin ? 3 g/dL
+Obtained with 21 days of registration: albumin: > 2.8 g/dl
+Within 10 days of treatment initiation: Albumin >= 2.5 mg/dL
+Albumin level ?3 g/dL
+Serum albumin ?2 g/dL.
+Within 10 days of treatment initiation: Albumin ? 2.5 mg/dL
+Albumin >= 2.0 g/dL
+Albumin ? 2.5 mg/dL
+Serum albumin >= 2.0 mg/dL
+Albumin >= 2.5 g/dL
+Albumin >= 3.0 mg/dL (performed within 10 days of treatment initiation)
+Albumin >= 3 g/dL.
+Within 7 days (+ 3 day window) of enrollment: Albumin >= 2.5 g/dl
+Within 7 days before the first dose of study treatment: Serum albumin >= 2.8 g/dl
+Albumin >= 2.5 mg/dL
+Albumin >= 2.5 mg/dL, performed within 10 days of treatment initiation
+Albumin > 25 g/L
+Serum albumin =< 3.0 g/dL unless prothrombin time is within the normal range
+Serum albumin < 2.5 g/dL
+Obtained =< 28 days prior to registration: Albumin >= 2.5 mg/dL
+Performed within 7 days of treatment initiation: Albumin >= 2.5 mg/dL
+Serum albumin >= 2.0 g/dL
+Serum albumin >= 3 g/dl
+Albumin >= 2.5 mg/dL
+Albumin >= 2.5 mg/dL, performed within 14 days of treatment initiation
+Albumin >= 2.5 mg/dL, performed within 10 days of treatment initiation
+Within 14 days prior to registration: Albumin >= 2.5 g/dL
+Within 14 days prior to cycle 1 day 1 of treatment: Serum albumin >= 2.5 g/dL
+Serum albumin >= 2.5 g/dl
+Albumin > 2.9 gm/dL
+(For both cohorts A and B): Serum albumin > 2
+Albumin >= 3.0 g/dL obtained < 4 weeks prior to starting treatment
+Albumin >= 2.5 g/dL
+Serum albumin >= 2 g/dL within 14 days of registration
+Albumin >= 2.0 g/dL
+Performed within 10 days of treatment initiation: Albumin >= 2.5 mg/dL
+Determined within 3 weeks of treatment initiation: Albumin >= 2.5 mg/dL
+Albumin >= 2.5 mg/dL within 14 days of treatment initiation
+Albumin ? 2 g/dL
+Albumin >= 2.5 mg/dL
+Albumin >= 2.5 mg/dL
+Albumin >= 2.5 mg/dL
+Albumin > 2.8 g/dl
+Serum albumin of > 3.0 g/dL
+Within 10 days of treatment initiation: Albumin >= 2.5 mg/dL
+Albumin >= 2.5 g/dL
+Within 14 days of treatment initiation: Albumin > 2.5 mg/dL
+Serum albumin >= 2 g/dL
+Serum albumin > 28 g/L
+Albumin > 2.5 g/dL (obtained within 28 days prior to first study treatment)
+Albumin >= 2.5 mg/dL, performed within 14 days of registration
+Albumin > 2.7 g/dL
+Performed within 10 days of treatment initiation: Albumin >= 2.5 mg/dL
+Albumin >= 2.8 mg/dL
+Albumin >= 2.5 mg/dL
+Albumin >= 2.5 mg/dL
+Albumin >= 2.5 mg/dL (performed within 28 days of registration)
+Albumin >= 2.0 mg/dL performed within 10 days of treatment initiation
+Albumin >= 2.5 mg/dL
+Albumin >= 2.5 mg/dL
+Albumin >= 2.5 mg/dL
+Albumin >= 2.5 mg/dL (within 10-15 days of treatment initiation)
+Albumin >= 2.5 mg/dL within 16 days of treatment initiation
+Serum albumin >= 3.0 g/dL
+Albumin >= 3 g/dL performed within 7 days of treatment initiation
+Albumin >= 2.5 mg/dL, during screening and on cycle 1, day 1
+Has laboratory evidence of hypercalcemia (>= 11mg/dl [in presence of normal albumin]) and/or hyperphosphatemia (>= 5.5)
+Albumin >= 2.5 mg/dL within 14 days of treatment initiation
+Albumin ? 3g/dL
+Albumin >= 3.3 mg/dL in the absence of dehydration (performed within 10 days of treatment initiation)
+Albumin < 2.5
+Albumin >= 2.5 mg/dL
+Serum albumin >= 2.8 g/dL
+Albumin >= 2.5 mg/dL
+Within 10 days of treatment initiation: Albumin >= 2.5 mg/dL
+Albumin: > 2.5 mg/dL
+Serum albumin < 3 g/dL
+Completed within 10 days of SBRT treatment initiation: Albumin >= 2.5 mg/dL
+Albumin >= 2.5 mg/dL
+Albumin > 2.8 g/dL.
+Serum albumin; if cirrhosis present: part of Child Pugh requirement; if no cirrhosis: albumin should be >= 2.5 g/dl
+Albumin >= 2.5 mg/dL
+Albumin >= 2.5 g/dL within 14 days of treatment initiation
+Serum albumin >= 2.5 mg/dL without intravenous supplementation
+Must have serum albumin > 2.5 mg/dL without intravenous supplementation
+Serum albumin >= 3.0 g/dL
+Albumin >= 2.5 mg/dL
+Albumin >= 2.5 mg/dL
+Albumin > 3.0 g/dl
+Serum albumin >= 3.0 g/dL
+Albumin > 2.5 mg/dL
+Albumin >= 2.5 mg/dL
+Serum albumin >= 3.0 g/dL
+Albumin >= 2.5 mg/dL, performed within 10 days of treatment initiation
+Albumin >= 2.5 mg/dL
+Albumin > 2.5 g/dL
+Serum albumin >= 2.8 g/dL
+Albumin >= 2.5 mg/dL
+Subjects with serum calcium (corrected for albumin) >= 12 mg/dL
+Performed within 14 days of treatment initiation: Albumin >= 3.0 mg/dL
+Albumin >= 2.5 mg/dL
+Albumin > 3.0 gm/dL
+Serum albumin >= 2.8 g/dL
+Serum albumin >= 2 g/dL within 7 days prior to enrollment
+Within 3 months of registration: Serum albumin > 3.0 g/dL
+Albumin >= 2.5 g/dL
+ARM A COHORT 1: Serum albumin >= 2.5 g/dL
+ARM B COHORT 2: Serum albumin >= 2.5 g/dL
+ARM B COHORT 3: Serum albumin >= 2.5 g/dL
+ARM C COHORT 4: Serum albumin >= 2.5 g/dL
+Albumin < 2.0 g/dL or < 20 g/L
+Any serum albumin is allowed, but >= 3.4 g/dL is strongly encouraged
+Serum/plasma albumin > 3.0 gm/dL
+Serum albumin must be greater than or equal to 2 g/dL
+For Part A participants: serum albumin >= 2 g/dL
+For Part B participants: serum albumin >= 2g/dL
+Serum albumin >= 3.0g/dL
+Serum albumin ? 2 g/dL.
+Albumin > 25 g/L
+Within 4 days prior to the first dose of cabozantinib: Serum albumin >= 2.8 g/dl
+Albumin >= 2.8 mg/dL
+Albumin >= 2.5 g/dL
+Albumin >= 2.5 mg/dL
+Albumin < 2.0 g/dL or < 20 g/L
+Albumin > 2.5 g/dL
+Albumin >= 2.5 g/dL
+Serum albumin ? 2.8 g/dL
+Serum albumin < 2.8 g/dL.
+Albumin >= 2.5 g/dL
+Serum albumin > 2.0 g/dl
+Serum albumin ?3.0 gm/dL.
+Serum albumin >= 2.0 g/dl
+Albumin > 2.4 g/dL
+Serum albumin >= 2 g/dL
+Albumin > 2.4 g/dL
+Albumin >= 2.0 g/dL or >= 20 g/L obtained =< 2 weeks prior to enrollment
+Serum albumin >= 3 g/dl
+Albumin > 2 g/dL
+Serum albumin of >= 3.0 g/dl
+Albumin >= 2 g/dl
+Albumin < 30 g/L (3.0 g/dL) at screening
+Albumin >= 2.5 g/dL
+Albumin >= 2 g/dL
+Albumin > 2.5 mg/dl
+Albumin >= 2g/dL
+Albumin > 3.0
+Low baseline albumin < 3.5 g/dl
+Serum albumin >= 2.5 g/dL
+Albumin ? 2.5 g/dL
+Albumin ? 2.5 mg/dL
+Baseline serum albumin > 30 g/L
+Serum albumin ?2 g/dL
+Albumin ?2.5mg/dL
+albumin ? 2.8 g/dL.
+Albumin >= 2.5 mg/dL
+Albumin > 2.7 g/dL (repeat if more than 3 days before the first dose)
+Hypoalbuminaemia (serum albumin < 30 g/L)
+Serum albumin ? 3.0 mg/dL.
+Albumin ? 2.5 mg/dL
+Albumin >= 3 g/dl
+Albumin ? 2.5 mg/dL
+Albumin >= 2.0 g/dL
+Serum albumin ? 3.0 g/dL
+Serum albumin >= 3g/dL
+Albumin >= 2.5 g/dL
+Albumin >= 2.5 g/dL
+Albumin > 2.7 g/dL
+Within 14 days prior to first dose of study drug treatment: Albumin >= 2.5 g/dL
+Within 7 days before the first dose of cabozantinib: Serum albumin >= 2.8 g/dl
+Calcium >= LLN (corrected for serum albumin, if albumin abnormal) =< 14 days prior to registration\r\n* NOTE: Supplementation may be given before the first dose of study medication
+Within 10 days of treatment initiation: albumin >= 3 mg/dL. Creatinine clearance should be calculated per institutional standard
+Albumin >= 2.5 mg/dL, performed within 28 days of treatment initiation
+Within 10 days of treatment initiation: Albumin >= 2.5 mg/dL
+Albumin >= 2.5 g/dL
+Serum albumin >= 2.5 g/dL
+Liver function tests performed within 3 weeks prior to starting study therapy must have albumin >= 2.5 g/dL
+Albumin >= 2.5 mg/dL
+Serum albumin >= 2 g/dL
+Albumin >= 3 g/dl
+Albumin >= 2.5 g/dl
+Within 7 days prior to study registration: Serum albumin >= 2 g/dL
+Serum albumin >= 3.0 g/dL
+Within 28 days of study registration: Albumin >= 3.0 g/dL
+Albumin >= 2.5 mg/dL
+Serum albumin >= 28 g/L
+Serum albumin >= 2 g/dL
+Albumin >= 2.5 mg/dL (performed within 10 days of treatment initiation)
+Albumin >= 2.5 gm/dl
+Albumin >= 2.5 mg/dL
+Albumin > 2 g/dL
+Albumin >= 2.5 g/dL
+Serum albumin >= 2.8 g/dL
+Albumin >= 2.5 mg/dL
+Albumin >= 2.5 mg/dL
+Within 30 days prior to treatment initiation: Albumin >= 2.5 mg/dL
+Albumin >= 3 mg/dl
+Albumin > 2.5 g/dL
+Albumin >= 2.5 mg/dL
+Calcium < 10.1 mg/dL (corrected to serum albumin)
+Serum albumin >= 2 g/dL
+Total calcium (corrected for serum albumin if albumin abnormal) above lower limit normal range for the institution; supplementation may be given before the first dose of study medication
+Decreased serum albumin < 30 g/L (< 3 g/dL)
+Serum albumin >= 2.5 g/dl
+Serum albumin > 3.0 g/dl within 14 days prior to registration
+Serum albumin >= 2 g/dL
+Albumin >= 3.0 g/dL
+Serum albumin >= 2 g/dL
+Patients on Part A and Part B: serum albumin >= 2 g/dL
+Patients on Part C with ALL: serum albumin >= 2 g/dL
+Albumin >= 2.5 g/dL
+Albumin >= 2.5 g/dL
+Albumin >= 2.5 g/dL
+Albumin >= 2.5 g/dL
+Serum albumin >= 2.8 g/dL
+Albumin < 2.0 g/dL or < 20 g/L
+Albumin >= 2.8 g/dL
+Serum albumin >= 2 g/dL
+Screening serum calcium levels < 2.20 mmol/L [8.8 mg/dL] (after correction for serum\n             albumin
+Albumin >= 2.5 g/dL
+Serum albumin > 3.0 g/dL
+Serum albumin >= 2 g/dL
+Albumin must be >= 3.0 gm/dL
+Albumin >= 3.0 gm/dL
+Albumin within institutional normal range
+Serum albumin less than (<) 2.5 grams per deciliter (g/dL).
+Serum albumin ? 3.0 g/dl
+Serum albumin ? 3.0 g/dl
+Serum albumin >= 2.8 g/dL
+Albumin ? 3.0 g/dL
+Albumin > 3.0 g/dL
+Serum Albumin >3g/dL
+Albumin >= 2.5 g/dL
+Serum albumin >= 3 g/dL
+Within 14 days prior to registration: Serum albumin >= 3.0 g/dL
+Subject has albumin < 3.0 g/dL (30 g/L).
+Serum albumin ? 3 g/dL
+Albumin < 3.0 g/dL (30 g/L) at screening;
+Serum albumin >= 3 g/dL
+Serum albumin >= 3.0 g/dl
+Albumin >= 2.5 mg/dL
+Serum albumin ? 3 g/dL.
+Albumin > 2.5 g/dL
+Serum albumin >= 2.5 g/dL, obtained within 14 days prior to initiation of study treatment
+Albumin ? 2.5 g/dL.
+Albumin >2.7 g/dL.
+Albumin ? 2 g/dl
+Albumin >= 2.8 g/dL
+Serum albumin >= 3.0 g/dL
+Has extensive metastatic tumor burden in the liver with serum albumin < 3.0 g/dL
+Albumin >= 2
+Albumin >= 2.5 g/dL
+Albumin >= 2.8 g/dL
+Serum albumin >= 2 g/dL
+Albumin >= 2.5 mg/dL (within 14 days prior to day 1 of protocol therapy)
+Serum albumin ?2.5 g/dl;
+Albumin >= 2.5 mg/dL (performed within 10 days of treatment initiation)
+Serum albumin > 3.0 g/dl
+Albumin >= 2.5 mg/dL, performed within 10 days of treatment initiation
+Albumin >= 2.5 mg/dL
+Serum albumin >= 2.5 g/dl
+Albumin >= 2.5 g/dL (within 14 days of treatment initiation)
+Albumin < 3 g/dL
+Within 72 h of initiating study treatment: Albumin >= 2.5 g/dL
+Albumin >= 2.5 mg/dL, should be performed within 28 days of treatment initiation, unless otherwise indicated
+Albumin >= 2.5 mg/dL
+Serum albumin <30 g/L (3.0 g/dL)
+Serum albumin > 30 g/L, or serum albumin = 30 g/L but normal prothrombin time
+Albumin < 2.8 g/dL (< 28 g/L)
+Albumin >= 2.5 g/dL
+Albumin <2.8
+Albumin >= 3 g/dl
+Serum albumin >= 2 g/dL
+Serum albumin >= 2.8 g/dl
+Albumin >= 3 g/dL
+Albumin >= 2.5 g/dL
+Albumin levels < 2.5 g/dl
+Serum albumin ?3.0 g/dL.
+Albumin >= 2 g/dl
+Serum albumin >= 2.8 g/dL
+Decreased serum albumin < 30 g/L (< 3 g/dL)
+Serum albumin >= 2 g/dL
+Albumin > 2.9 gm/dL
+Albumin >= 3.0 g/dL
+Albumin >=2.5 g/dL
+Albumin > 25 g/L
+Serum albumin >= 3.0 g/dL
+Serum albumin ? 2.5 g/dL
+Albumin >= 2.5 g/dL
+Serum albumin less than (<) 2.5 grams per deciliter (g/dL)
+Calcium < 10.1 mg/dL (corrected to serum albumin)
+Serum albumin >= 2 g/dL
+Severe hypoalbuminemia (albumin < 3.0 g/dL);
+Albumin ? 3.0 mg/dL;
+Serum albumin >= 2.8 g/dl
+Serum albumin ?3.0 gm/dL.
+Serum albumin >= 3.0 g/dL
+Albumin >= 2.5 g/dL
+Albumin > 2.7 g/dL (repeat if more than 7 days before the first dose)
+Albumin >= 3 g/dl
+Serum albumin >= 3.0 g/dL
+Serum albumin of > 3.0 g/dl
+Serum albumin must be > 2.5 g/dl
+Albumin > 3.0 g/dL or > 30 g/L
+Serum albumin >= 3.5 g/dL
+Albumin >= 2.5 g/dL\r\n* NOTE: this applies to patient in the normal and renal dysfunction cohorts (N, R3 and R4); abnormal albumin is allowed for patients in the liver dysfunction cohorts
+Serum albumin >= 2.5 g/dL
+Patients must have a serum albumin >= 2.5 g/dL within 28 days prior to registration
+Albumin > 2 g/dL
+Serum albumin >= 2 g/dl
+Serum albumin\r\n* If cirrhosis present: part of Child Pugh requirement\r\n* If no cirrhosis: albumin should be >= 2.5 g/dl
+Serum albumin ? 2.0 gm/dL.
+Serum albumin > 2.8 g/dL
+Serum albumin >= 2 g/dL
+Serum albumin ?3.0 gm/dL.
+Albumin ? 2.8 g/dL
+Serum albumin >= 3.0 g/dL
+Albumin >= 2.5 g/dL
+Albumin >= 2.5 g/dL
+Total calcium (corrected for serum albumin)
+Albumin < 30 g/L (3.0 g/dL)
+Serum albumin >= 2.8 g/dL
+Albumin >= 3.0
+Albumin =< 2.5 g/dL
+Albumin >= 2 g/dL
+Albumin: > 2.5 g/dL
+Serum albumin >= 2.8 g/dl
+Serum albumin <3.0 g/dL unless prothrombin time is within the normal range.
+Serum albumin >= 2 g/dL
+Albumin >= 2.5 g/dl
+Albumin > 3.0 g/dl
+Serum albumin >= 2.8 g/dl
+Albumin > 3.0 g/dl
+Albumin > 3.0 g/dl
+Albumin ? 2.8 g/dL
+Albumin >= 2.6 g/dL
+Albumin >= 3 mg/dL
+Albumin >= 2.5 mg/dL
+Albumin >= 2.5 mg/dL
+Albumin < 30 g/L (3.0 g/dL) at screening.
+Serum albumin ? 2.0 gm/dL.
+Serum albumin > 2 g/dL
+Albumin ? 3g/dL
+Albumin ? 3g/dL
+Albumin >= 2.5 mg/dl
+Albumin < 2.0 g/dL or < 20 g/L
+Albumin >= 2.5 g/dL
+Serum albumin less than 2 g/dL
+Serum albumin >= 2.8 g/dL
+Albumin >= 2.5 g/dL
+Serum albumin ? 30 g/L
+Serum Albumin >3.0 gm/dL
+RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Albumin >= 3 g/dl
+NON-PROGRESSED DIPG (STRATUM 2): Albumin >= 3 g/dl
+Albumin >= 2.5 mg/dL within 7 days of treatment initiation
+Serum albumin >= 2.5 g/dl
+Within 14 days prior to first study treatment: Albumin >= 3.5 g/dL
+Serum albumin >= 2.8 g/dL
+Albumin > 3.0 g/dl
+Serum albumin >= 2.8 g/dL
+Serum albumin > 2 g/dL
+Serum albumin >= 2 g/dL
+Albumin >= 2 g/dL
+Serum albumin > 3.0 g/dL
+Albumin ? 2.5 g/dL
+Serum albumin <3.0 g/dL.
+Albumin >= 3.0 mg/dl
+Serum albumin < 3.0 gm/dL.
+Serum albumin > 2 g/dL
+Albumin >= 3.0 g/dL
+Serum albumin < 2.5 g/dL
+Serum albumin of >= 3.0 g/dL
+serum albumin ?3 g/dL
+Serum albumin < 2.5 g/dL
+Serum albumin > 2.5 g/dl
+Serum albumin ?3.2 g/dL in the absence of receipt of (IV) albumin within the previous 72 hours.
+Serum albumin >= 2.8 g/dL
+Serum albumin >= 3 g/dL
+Albumin >= 2 g/dL
+Serum albumin of >= 3.0 g/dL
+Albumin should be >= 3
+Subjects with serum calcium (corrected for albumin) ? 12 mg/dL.
+Patients must have bilirubin < 1.5 mg/dL, transaminases < 2.5 X ULN, albumin > 3 gm/dL, creatinine < 2.0 mg/dL. Patients who have had albumin < 3 gm/dL boosted by an albumin infusion must be observed to maintain albumin at > 3gm dL for 30 days without an additional infusion.
+Serum albumin < 3.0 g/dL
+Serum albumin < 2.5 g/dL
+Albumin >= 2.5 mg/dL
+Albumin >= 2.5 mg/dL
+Serum albumin >= 2 g/dL
+Albumin > 25 g/L
+Albumin ? 3.0 mg/dL;
+Albumin >= 2.5 g/dL within 28 days prior to registration
+Serum albumin >= 2 g/dL
+Serum albumin >= 3.0 g/dL
+Serum albumin >= 3.0
+Albumin < 3.5
+Urinary albumin > 1 g/day
+Serum albumin < 3.0
+Serum albumin =< 2.0 g/dL
+Albumin < 3 gm/dL
+Albumin >2.8 grams per deciliter (g/dL)
+Albumin >= 3.0 g/dL, obtained within 14 days of the first dose of study drug
+Albumin >= 3 g/dL
+Serum albumin >= 3.0 g/dL
+Participants in the dose escalation cohort must have a serum albumin of ? 3.2 g/dL at screening.
+A serum albumin greater than or equal to 2.5 g/dL
+Albumin > 2.8 g/dl
+Albumin > 3.4
+Serum calcium or albumin adjusted >= 8.0 mg/dL and =< 11.5 mg/dL
+Albumin >= 3.5 mg/dL
+Albumin > 2.5 g/dl
+Albumin >= 2.5 g/dL
+Obtained within 28 days prior to registration: Albumin > 2.5 g/dL
+Serum albumin ? 3.0 g/dL
+Albumin of >= 2.5 mg/dl
+Albumin within 2 x ULN
+Albumin of >= 2.5 g/dl
+Plasma albumin >= 3 g/dL
+Plasma albumin < 3 g/dL
+Albumin >= 2.5 g/dl
+Albumin >= 2.5 mg/dL, obtained within 14 days prior to C11-AMT PET scan
+Serum albumin > 3.0g/dL
+Albumin < 3 g/dl obtained < 2 weeks prior to study enrollment
+Albumin < 3 g/dl
+Albumin < 2 g/dl
+Albumin < 2 g/dl
+Serum albumin >= 30 g/L
+Albumin < 2 g/dl
+Albumin < 2 g/dL
+Albumin >= 3.2 g/dL (in the absence of receipt of intravenous albumin in the previous 72 hours)
+Serum albumin > 2 g/dL
+Albumin >= 2.5 mg/dL, obtained =< 30 days prior to registration
+Albumin >= 2.8 mg/dL, performed within 10 days of treatment initiation
+Albumin ? 2.5 mg/dL
+Albumin > 30 g/L (3.0 g/dL) at the screening visit
+Albumin >= 2.5 g/dL
+Albumin >= 2.5 g/dL
+Hypoalbuminemia (albumin < 3.5 g/dL)
+Albumin ? 2.5 g/dl.
+serum albumin >2g/dL
+Total calcium (corrected for serum albumin)
+Albumin >= 2.8 mg/dL
+Albumin >= 2.5 mg/dL
+Albumin >= 2.5 mg/dL, performed within 10 days of protocol enrollment